[Federal Register Volume 69, Number 17 (Tuesday, January 27, 2004)]
[Notices]
[Page 3946]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-1651]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec. 1301.33(a) of title 21 of the Code of Federal 
Regulations (CFR), this is notice that on September 25, 2003, Cambrex 
North Brunswick, Inc., Technology Center of New Jersey, 661 Highway 
One, North Brunswick, New Jersey 08902, made application by letter to 
the Drug Enforcement Administration (DEA) for registration as a bulk 
manufacturer of Sufentanil (9740), a basic class of Schedule II 
controlled substance.
    The firm plans to manufacture Sufentanil to distribute in bulk to 
its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substance may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: Federal Register Representative, 
Office of Chief Counsel (CCD) and must be filed no later than March 29, 
2004.

    Dated: December 19, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-1651 Filed 1-26-04; 8:45 am]
BILLING CODE 4410-09-M